RF1AG090598
Project Grant
Overview
Grant Description
TRNA FRAGMENTS AND THEIR ROLE IN TAU PATHOLOGY IN ALZHEIMER'S DISEASE AND TAUOPATHIES - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) POSE SIGNIFICANT CHALLENGES WITH A GROWING SOCIETAL IMPACT. ADDRESSING THESE CHALLENGES REQUIRES COMPREHENSIVE RESEARCH INTO THE NEUROBIOLOGY OF THE DISEASES, LEADING TO INNOVATIVE BIOMEDICAL CONCEPTS, APPROACHES, AND MOLECULAR TARGETS. A CENTRAL FACTOR IN THESE DISORDERS IS THE PROTEIN TAU, WHOSE MISREGULATED HOMEOSTASIS, AGGREGATION, AND INTERCELLULAR SPREAD CONTRIBUTE TO AD, FRONTOTEMPORAL DEMENTIA (FTD), AND OTHER TAUOPATHIES. TAU-CONTAINING NEUROFIBRILLARY TANGLES (NFTS) FROM AD BRAINS ARE KNOWN TO CONTAIN RNA, AND IT IS PROPOSED THAT TAU-RNA INTERACTIONS MAY FACILITATE TAU AGGREGATION AND MODULATE NEURONAL VULNERABILITY TO STRESS. HOWEVER, THE SPECIFIC RNA SPECIES INVOLVED IN TAU PATHOLOGY REMAIN UNIDENTIFIED. OUR DATA SUGGEST A NOVEL CLASS OF SMALL RNA TRANSCRIPTS—TRNA-DERIVED FRAGMENTS (TRFS)—THAT ACCUMULATE IN AD, POTENTIALLY BINDING TAU AND PROMOTING ITS MISFOLDING AND AGGREGATION. REGULATED BY DISEASE-RELATED NEURONAL STRESS, TRFS ARE ENRICHED IN EXTRACELLULAR SPACES AND BODY FLUIDS, INCLUDING CEREBROSPINAL FLUID (CSF), AND CAN BE TAKEN UP BY RECIPIENT NEURONS. OUR RESEARCH AIMS TO INVESTIGATE THE ROLE OF SPECIFIC TRFS IN TAU AGGREGATION, PATHOLOGY PROPAGATION, AND NEURODEGENERATION IN ADRD THROUGH THE FOLLOWING SPECIFIC AIMS. SPECIFIC AIM 1: CHARACTERIZE THE SMALL RNA LANDSCAPE, WITH A FOCUS ON TRFS, AT DIFFERENT STAGES OF AD PATHOLOGY USING AN OPTIMIZED RNA SEQUENCING PLATFORM. EXAMINE THE RNA BINDING CAPACITY OF INTRACELLULAR AND EXTRACELLULAR TAU VARIANTS AND MUTANTS USING HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED NEURONS AND RODENT PRIMARY NEURONS. IDENTIFY TRFS WITHIN PATHOLOGICAL TAU AGGREGATES AND VISUALIZE THEIR COLOCALIZATION WITH TAU PATHOLOGY IN HUMAN AD BRAINS. SPECIFIC AIM 2: INVESTIGATE THE IMPACT OF SELECTED TRFS AND TRF-ENRICHED EXTRACELLULAR COMPLEXES ON TAU HOMEOSTASIS AND PATHOLOGY USING GAIN- AND LOSS-OF-FUNCTION APPROACHES IN NEURONAL CELL MODELS. SPECIFIC AIM 3: EXAMINE THE EFFECTS OF SPECIFIC TRFS ON TAU PATHOLOGY AND BEHAVIORAL PHENOTYPES IN WT MICE AND A HUMANIZED TAU P301S/PS19 MOUSE MODEL OF TAUOPATHY AND NEURODEGENERATION. ASSESS NEUROPROTECTIVE EFFECTS OF TARGETING SPECIFIC TRFS IN THE BRAIN. THIS COLLABORATIVE R01 PROJECT SEEKS TO UNRAVEL THE COMPLEX MOLECULAR MECHANISMS UNDERLYING ADRD AND EXPLORE THE CELLULAR AND EXTRACELLULAR BIOLOGY OF THESE DISORDERS. FINDINGS MAY REVEAL A NEW CLASS OF POTENTIAL THERAPEUTIC TARGETS AND BIOMARKERS.
Awardee
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Massachusetts
United States
Geographic Scope
State-Wide
Related Opportunity
Brigham & Womens Hospital was awarded
Tau Fragment RNA: Novel Targets in Alzheimer's Disease Research
Project Grant RF1AG090598
worth $3,672,952
from National Institute on Aging in September 2025 with work to be completed primarily in Massachusetts United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
9/1/25
Start Date
8/31/29
End Date
Funding Split
$3.7M
Federal Obligation
$0.0
Non-Federal Obligation
$3.7M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
RF1AG090598
SAI Number
RF1AG090598-3172647107
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
QN6MS4VN7BD1
Awardee CAGE
0W3J1
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 9/5/25